Real-World Patient Perceptions of GLP-1 RAs and SGLT-2is with Cardiorenal Benefits

被引：0
|
作者：
Lambert, Natalie
Clark, Callahan
McCoy, Rozalina G.
Wong, Alyssa
Cook, David J.
机构：
来源：
DIABETES | 2022年 / 71卷
关键词：
D O I：
10.2337/db22-618-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
618-P
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Do GLP-1RAs and SGLT-2is reduce cardiovascular events in women with type 2 diabetes? A systematic review and meta-analysis
    Mishriky, B. M.
    Okunrintemi, V
    Jain, S.
    Sewell, K. A.
    Powell, J. R.
    Cummings, D. M.
    DIABETES & METABOLISM, 2021, 47 (01)
  • [42] Combined treatment with SGLT2i and GLP1ra compared with SGLT2i or GLP1ra alone improves survival: a Real-World Registry
    Garcia Vega, D.
    Cinza-Sanjurjo, S.
    Eiras, S.
    Gonzalez-Juanatey, J. R.
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 : 591 - 591
  • [43] GLP-1 RAs and SGLT2-Is to Lower Glucose and Reduce the Risk of Cardiovascular and Diabetic Kidney Disease
    Morrison, Leigh
    Gabison, Jonathan
    Oshman, Lauren
    JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE, 2024, 37 (03) : 372 - 382
  • [44] Management of acute kidney disease in type 2 diabetes: the potential role of GLP-1 RAs and SGLT2-Is
    Giugliano, Dario
    Esposito, Katherine
    De Nicola, Luca
    JOURNAL OF NEPHROLOGY, 2024, 37 (08) : 2347 - 2350
  • [45] Real-World Patterns in GLP-1 RA Switching From 2018-2023 in the US
    Cartwright, Brianna M.
    Rodriguez, Patricia J.
    Gratzl, Samuel
    Do, Duy
    Baker, Charlotte
    Stucky, Nicholas
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 582 - 583
  • [46] Success of Aligned Clinician-Patient Education Improves Clinicians' Ability to Use GLP-1 RAs in Practice and Patients' Understanding of GLP-1 RAs
    Larkin, Amy
    Le, Anne
    DIABETES, 2022, 71
  • [47] GLP-1 Receptor Agonists and SGLT-2 Inhibitors as Adjuncts to Insulin in Type 1 Diabetes: Benefits and Concerns
    Dimitriadis, George D.
    Lambadiari, Vaia
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2023, 108 (04): : E52 - E53
  • [48] Do GLP-1RAs and SGLT-2is reduce cardiovascular events in black patients with type 2 diabetes? A systematic review and meta-analysis
    Mishriky, Basem M.
    Powell, James R.
    Wittwer, Jennifer A.
    Chu, Jennifer X.
    Sewell, Kerry A.
    Wu, Qiang
    Cummings, Doyle M.
    DIABETES OBESITY & METABOLISM, 2019, 21 (10): : 2274 - 2283
  • [49] GLP1 Receptor Agonist and SGLT2 Inhibitor Combination: An Effective Approach in Real-world Clinical Practice
    Diaz-Trastoy, Olaia
    Villar-Taibo, Rocio
    Sifontes-Dubon, Mildred
    Mozo-Penalver, Hector
    Bernabeu-Moron, Ignacio
    Cabezas-Agricola, Jose M.
    Munoz-Leira, Virginia
    Peino-Garcia, Roberto
    Martis-Sueiro, Aurelio
    Garcia-Lopez, Jose M.
    Martinez-Olmos, Miguel A.
    CLINICAL THERAPEUTICS, 2020, 42 (02) : E1 - E12
  • [50] Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: Potential Benefits in Surrogate and Hard Endpoints
    Doumas, Michael
    Imprialos, Konstantinos
    Stavropoulos, Konstantinos
    Reklou, Andromachi
    Sachinidis, Alexandros
    Athyros, Vasilios G.
    CURRENT PHARMACEUTICAL DESIGN, 2018, 24 (17) : 1879 - 1886
12345